Meropenem microbiology: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Meropenem}} | |||
{{CMG}} | |||
==Microbiology== | ==Microbiology== | ||
| Line 7: | Line 14: | ||
Meropenem should not be used to treat methicillin-resistant [[staphylococci]] (MRSA). | Meropenem should not be used to treat methicillin-resistant [[staphylococci]] (MRSA). | ||
In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some | In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some | ||
isolates of [[Pseudomonas aeruginosa]]. | isolates of [[Pseudomonas aeruginosa]].<ref>{{Cite web | last = | first = |title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf | publisher = |date = | accessdate = }}</ref> | ||
==References== | |||
{{Reflist}} | |||
{{FDA}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 21:50, 20 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Microbiology
Meropenem is a broad-spectrum Carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and [[Pseudomonas aeruginosa]]; and PBPs 1, 2 and 4 of Staphylococcus aureus. Bactericidal concentrations (defined as a 3 log10 reduction in cell counts within 12 to 24 hours) are typically 1-2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes against which lethal activity is not observed. Meropenem has significant stability to hydrolysis by β-lactamases of most categories, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant staphylococci (MRSA). In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some isolates of Pseudomonas aeruginosa.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.